SCHEMBL2105218

SCHEMBL2105218

CCN1CCN(c2ccc(S(=O)(=O)[C@H]3CN[C@H](C(=O)NC4(C#N)CC4)C3)c(Cl)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CTSS P25774 20/20 0.52
CTSL P07711 3/20 0.46
CTSB P07858 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL699204 0.89 CTSS (0.56) CTSSCTSLCTSB
SCHEMBL2105969 0.89 CTSS (0.57) CTSSCTSLCTSB
SCHEMBL15327206 0.87 CTSS (0.47) CTSSCTSLCTSB
SCHEMBL2105333 0.86 CTSS (0.56) CTSSCTSLCTSB
SCHEMBL1139592 0.86 CTSS (0.56) CTSSCTSLCTSB
SCHEMBL1139358 0.86 CTSS (0.56) CTSSCTSLCTSB
SCHEMBL2106670 0.85 CTSS (0.57) CTSSCTSLCTSB
SCHEMBL3060725 0.84 CTSS (0.40) CTSS
SCHEMBL2106066 0.83 CTSS (0.58) CTSSCTSLCTSB
SCHEMBL15184110 0.82 CTSS (0.61) CTSSCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US claimed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 CTSS 1542/4885CTSL 178/4885CTSB 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.